Use of aspirin, β-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: Missed opportunities for prevention?

Archives of Internal Medicine

Volumn 159, Issue 6, 1999, Pages 561-567

  McCormick, Danny ^a,b   Gurwitz, Jerry H ^a,b   Lessard, Darleen ^a   Yarzebski, Jorge ^a   Gore, Joel M ^a   Goldberg, Robert J ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; WARFARIN;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ARTICLE; DRUG USE; FEMALE; HEART REINFARCTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTILIPEMIC AGENTS; ASPIRIN; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PATIENT ADMISSION; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0033594179     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.6.561     Document Type: Article

References (44)

1. Collaborative overview of randomized controlled trials of anti-platelet therapy in various categories of patients. BMJ. 1994;308:81-106.
2. Becker RC. Antiplatelet therapy in coronary heart disease. Arch Pathol Lab Med. 1993;117:89-96.
3. Yusel S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease, I: treatments following myocardial infarction. JAMA. 1988;260: 2088-2093.
4. Pederson TR. Six-year follow-up of the Norwegian multicenter study on timolol after acute myocardial infarction. N Engl J Med. 1985;313:1055-1058.
5. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in myocardial infarction: a double-blind randomized trial. Lancet. 1981;2:823-827.
6. Beta-blocker Heart Attack Study Group. The Beta-blocker Heart Attack Trial. JAMA. 1981;246:2073-2074.
7. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-807.
8. Yusef S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction. Prog Cardiovasc Dis. 1985;27:335-371.
9. The Beta-blocker Pooling Project Research Group. The Beta-blocker Pooling Project (BBPP). Eur Heart J. 1988;9:8-16.
10. Holm I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation. 1990; 82:1916-1924.
11. Scandanavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandanavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
12. Sachs FM, Pfeffer MA, Moye LA, et al. The effect of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
13. National Cholesterol Education Program Expert Panel. Second Report on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1333-1445.
14. Gunnar RM, Bourdillon PVD, Dixon DW, et al. ACC/AHA guidelines for the early management of patients with acute myocardial infarction. J Am Coll Cardiol. 1990; 16:249-292.
15. ACC/AHA Task Force. Guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol. 1996;28:1328-1428.
16. National Cholesterol Education Program Expert Panel. Report on detection, evaluation and treatment of high blood cholesterol in adults. Arch Intern Med. 1988; 148:36-69.
17. Malone ML, Sial SH, Battiola RJ, Nachodsky JP, Solomon DJ, Goodwin JS. Age-related differences in the utilization of therapies post acute myocardial infarction. J Am Geriatr Soc. 1995;43:627-633.
18. Ellerbeck EF, Jenks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction. JAMA. 1995;273:1509-1514.
19. Krumholz HM, Radford MJ, Ellerbeck EF, et al. Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. Ann Intern Med. 1996;124:292-298.
20. Sial SH, Malone M, Freeman JL, Battiola R, Nachodsky J, Goodwin JS. Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction. J Gen Intern Med. 1994;9:599-605.
21. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA. 1997;277:115-121.
22. Viskin S, Kitzis I, Lev E, et al. Treatment with β-adrenergic blocking agents after myocardial infarction. J Am Coll Cardiol. 1995;25:1327-1332.
23. Brand DA, Newcomer LN, Freiburger A, Tian H. Cardiologists' practices compared with practice guideline: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol. 1995;26:1432-1436.
24. Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction: incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med. 1991;325:1117-1122.
25. Goldberg RJ, Gore JM, Alpert JS, Dalen JE. Non-Q wave myocardial infarction: recent changes in occurrence and prognosis: a community-wide perspective. Am Heart J. 1987;113:273-279.
26. Goldberg RJ, Gore JM, Gurwitz JH, et al. Impact of age on the incidence and prognosis of initial acute myocardial infarction: the Worcester Heart Attack Study. Am Heart J. 1989;117:543-549.
27. Gurwitz JH, Goldberg RJ, Chen Z, Gore JM, Alpert JS. Recent trends in hospital mortality of acute myocardial infarction: have improvements been realized for all age groups? the Worcester Heart Attack Study (1975-1990). Arch Intern Med. 1994;154:2202-2208.
28. Col NF, McLaughlin TJ, Soumerai SB, et al. The impact of clinical trials on the use of medications for acute myocardial infarction: results of a community-based study. Arch Intern Med. 1996;156:54-60.
29. World Health Organization. International Classification of Diseases, Ninth Revision (ICD-9). Geneva, Switzerland: World Health Organization; 1977.
30. Goldberg RJ, Gore JM, Alpert JS, Dalen JE. Recent changes in attack and survival rates of acute myocardial infarction (1975-1981): Worcester Heart Attack Study. JAMA. 1986;255:2774-2779.
31. Goldberg RJ, Gore JM, Alpert JS, Dalen JE. Incidence and case fatality rates of acute myocardial infarction (1975-1984): Worcester Heart Attack Study. Am Heart J. 1988;115:761-767.
32. Goldberg RJ, Gorak EJ, Yarzebski J, et al. A community-wide perspective of gender differences and temporal trends in the incidence and survival rates following acute myocardial infarction and out-of-hospital deaths due to coronary heart disease. Circulation. 1993;87:1947-1953.
33. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau J-L, Braunwald E. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med. 1992;327:241-247.
34. Cohen MV, Byrne M, Levine B, Gutowski T, Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation. 1991;33:1294-1304.
35. Pashos CL, Newhouse JP, McNeil BJ. Temporal changes in the care and outcomes of elderly patients with acute myocardial infarction, 1987 through 1990. JAMA. 1993;270:1832-1836.
36. Phillips BG, Yim JM, Brown EJ, et al. Pharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals. Am Heart J. 1996; 131:872-878.
37. Montague TJ, Ikuta RM, Wong RY, Bay KS, Teo KK, Davies NJ. Comparison of risk and patterns of practice in patients older and younger than 70 years with acute myocardial infarction in a two-year period (1987-1989). Am J Cardiol. 1991;68:843-847.
38. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. JAMA. 1992;268:240-248.
39. Jansen RWMM, Gurwitz JH. Controversies surrounding the use of beta blockers in older patients with cardiovascular disease. Drugs Aging. 1994;4:175-183.
40. Schwarts LM, Fisher ES, Tosteson ANA, et al. Treatment and health outcomes of women and men in a cohort with coronary artery disease. Arch Intern Med. 1997;157:1545-1551.
41. Beta-blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction, I: mortality results. JAMA. 1982; 247:1707-1714.
42. Sanz G, Pajaron A, Alegria E, et al. Prevention of early aortocoronary bypass occlusion by low-dose aspirin and dipyridamole. Circulation. 1990;82:765-773.
43. The Coronary Drug Project Research Group. Aspirin in coronary heart disease. J Chronic Dis. 1976;29:625-642.
44. Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995;332:1125-1131.